Indaptus Therapeutics
INDP
26 hedge funds and large institutions have $65.6M invested in Indaptus Therapeutics in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 5 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
13% more funds holding
Funds holding: 23 → 26 (+3)
2% less capital invested
Capital invested by funds: $66.7M → $65.6M (-$1.09M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$5.57M |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$4.18M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$2.82M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$2.17M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$316K |
| 2 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$175K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$173K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$155K |
| 5 |
JP Morgan Chase
New York
|
-$138K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Geode Capital Management
Boston,
Massachusetts
| $55K | +$66.5K | +6 | New |
|
27
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
AFM
28
Anson Funds Management
Dallas,
Texas
| – | -$316K | -22 | Closed |
|
|
EMG
29
ETF Managers Group
Summit,
New Jersey
| – | -$175K | -13 | Closed |
|
|
30
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$173K | -12 | Closed |
|
|
31
JP Morgan Chase
New York
| – | -$138K | -10 | Closed |
|
|
ARTA
32
A.R.T. Advisors
New York
| – | -$85K | -6 | Closed |
|
INDP Hedge Fund Activity: Q2 2018 in Review
26 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q2 2018, worth a combined $65.6M — down 1.6% from $66.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new INDP positions and 5 closed out — a net gain of 3 holders — while 11 added to existing stakes and 4 trimmed.
The largest buyer was Prosight Management, opening a new position worth an estimated $5.57M. The largest seller was Anson Funds Management, exiting entirely with an estimated $316K sold.
- 26 institutional investors held Indaptus Therapeutics (INDP) as of Q2 2018, up from 23 in Q1 2018.
- Funds reported $65.6M of Indaptus Therapeutics stock for Q2 2018, down 1.6% quarter-over-quarter.
- 8 funds opened new Indaptus Therapeutics positions in Q2 2018 and 5 closed out, a net change of +3 holders.
- The largest Indaptus Therapeutics buyer in Q2 2018 was Prosight Management, an estimated $5.57M added.
- The largest Indaptus Therapeutics seller in Q2 2018 was Anson Funds Management, an estimated $316K sold.
Based on aggregated 13F filings for Q2 2018.